Please assess the completion status of the following clinical trial:

Trial Title: Fingolimod Effect on Cytokine and Chemokine Levels

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~1. Written informed consent must be obtained before the beginning of te study~2. Nonresponder RRMS patients~3. Last relapse of the patient should be at least 2 months before study entry.~4. Last interferon or glatiramer acetate dose of the patient should be at least 1 month before study entry.~Key Exclusion Criteria:~1. Patients with secondary progressive MS.~2. Patients with known contraindications for fingolimod treatment.~3. Other coexistent autoimmune diseases~4. Pregnant or nursing (lactating) women

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- FTY720 (Type: EXPERIMENTAL): None
- Healthy volunteers (Type: NO_INTERVENTION): Healthy volunteers with no intervention or drug administered.

Based on this trial design, predict the completion outcome and termination type (if applicable).